Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Novavax Inc

NVAX

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Last trade $8.01
Day change -$0.05 (-0.62%)
Day range $7.88 – $8.25
Volume 2,204,308
Market cap $1.33B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.33B
Price / earnings
—
Price / book
-6.13×
Price / sales
3.23×
EV / sales
3.41×
EV / EBITDA
-19.4×

Profitability

Earnings per share
-$0.46
Return on assets
-8.64%
Return on equity
35.38%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-1.36×
Current ratio
2.15×
Quick ratio
2.09×
Cash ratio
0.67×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$244.08M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NVAX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$68.3M$56.7M$139.51M$147.14M$70.45M$239.24M$666.66M$88.31M
Cost of revenue$23.49M$14.25M$30.7M$22.1M$21.5M$15.33M$14.12M$36.67M
Gross profit$44.81M$42.45M$108.82M$125.04M$48.95M$223.92M$652.54M$51.64M
Selling, general and administrative$23.65M$26.67M$28.78M$34.12M$31.66M$43.61M$48.09M$78.34M
Research and development$52.45M$70.69M$95.47M$75.88M$98.27M$79.23M$88.94M$104.38M
Total operating expenses$76.09M$97.36M$124.25M$110.81M$226.97M$122.85M$137.03M$182.72M
Operating income-$31.28M-$54.91M-$15.43M$14.23M-$178.02M$101.07M$515.51M-$131.08M
Interest expense-$5.4M-$5.69M-$4.9M-$5.82M-$5.48M-$5.52M-$5.72M-$7.59M
Income before taxes-$29.65M-$51.68M-$8.51M$17.9M-$203.04M$107.45M$519.85M-$73.58M
Income taxes$1.72M$1.71M$985K$376K-$657K$946K$1.2M$7.45M
Net income-$31.38M-$53.39M-$9.49M$17.53M-$202.38M$106.51M$518.65M-$81.03M
Net income attributable to common shareholders-$31.38M-$53.39M-$9.49M$17.53M-$202.38M$106.51M$518.65M-$81.03M
EBITDA-$28.23M-$51.85M-$12.37M$20.16M-$74.4M$108.63M$523.85M-$118.56M
Basic earnings per share-$0.19-$0.32-$0.06$0.11-$1.25$0.66$3.22-$0.51
Diluted earnings per share-$0.19-$0.32-$0.06$0.10-$1.25$0.62$2.93-$0.57

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax has been a trending stock, but shares have declined 14% over the past month, underperforming the S&P 500's -3.3% decline. While the company shows strong earnings estimate revisions and has beaten consensus estimates in recent quarters, it carries a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market. The stock is valued at par with peers and faces projected revenue declines of 58.4% and 42.4% for the current and next fiscal years, respectively.

Zacks Investment Research

NVAX Stock Falls 8% Despite Q3 Earnings & Sales Beat, Costs Decline

Novavax reported Q3 2026 loss of 19 cents per share, beating estimates, with revenues of $68 million exceeding consensus. The company raised 2026 revenue guidance to $385-$415 million, primarily driven by a $125 million Sanofi milestone. Despite operational improvements and cost reductions, shares fell 8.2% as investors focused on the one-time nature of the milestone and dependence on a potential 2029 U.S. vaccine launch for profitability.

Zacks Investment Research

Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know

Novavax stock declined 3.09% to $9.40, underperforming the broader market which gained 0.7%. The vaccine maker has lost 8.75% over the past month and faces headwinds with expected quarterly revenue down 28.15% year-over-year to $50.61 million. However, consensus EPS estimates have shifted upward 16.88% over the past month, and the stock holds a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?

Biogen shares surged 5.3% to $253.84 driven by positive phase II data from its AMETHYST study for litifilimab in cutaneous lupus erythematosus, with phase III data expected in H1 2027. However, the company's consensus EPS estimate was revised 1.8% lower over the past month, which could limit further price appreciation. Novavax declined 9.3% to $9.99 with its EPS estimate revised down 8.1% over the past month.

The Motley Fool

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Moderna's stock fell 18% after reports of a data leak regarding its personalized melanoma vaccine showed a 42% reduction in recurrence or death risk when paired with Merck's Keytruda—lower than Phase II results of 49%. The full Phase 3 results were scheduled for release on October 24, and the leaked figures fell short of market expectations despite the company's 600% gain in 2026.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Dec 13, 2007$2.125Dec 31, 2007unknown
Nov 13, 2007$2.125Nov 30, 2007unknown
Oct 11, 2007$2.125Oct 31, 2007unknown
Sep 13, 2007$2.125Sep 28, 2007recurring
Aug 13, 2007$2.125Aug 31, 2007recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 10, 20191-for-20reverse split